Axokine (Regeneron).
Axokine, a second-generation neurotrophic factor that is related to ciliary neurotrophic factor (CNTF), is under development by Regeneron for the potential treatment of obesity and associated complications such as type 2 diabetes.
Preti
Antonio
A
Genneruxi Medical Center, Via Costantinopoli 42, I-09129 Cagliari, Italy. apreti@tin.it
D000818:Animals; D001067:Appetite Depressants / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D015992:Body Mass Index; D020934:Ciliary Neurotrophic Factor / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy; D004195:Disease Models, Animal; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
D001067:Appetite Depressants; D020934:Ciliary Neurotrophic Factor; C118937:axokine